Screening for Neurotoxic Disease in Humans

Joseph C. Arezzo, Herbert H. Schaumburg

Research output: Contribution to journalArticle

Abstract

Detection of neurotoxic disease is a formidable task requiring clinical, epidemiologic and detective skills,(1) Rarely does neurotoxic insult occur in isolation, and rarely are precise details of the putative exposure known. False positive and false negative diagnoses of neurotoxicity are common because of the similarity of the major signs and symptoms with those associated with metabolic, traumatic, or age-related diseases. No single test or sign is pathognomonic for neurotoxic disease; routine clinical laboratory results and imaging procedures are generally of Little value. Exposure to a specific toxin can result in a vastly different clinical profile depending on the magnitude and route of exposure. For example, acute high level exposure to acrylamide causes a toxic encephalopathy with convulsions and hallucinations; prolonged low level exposure causes distal sensory loss. Since metabolites are often the toxic moiety, it is rarely possible to predict neurotoxicity by examining the chemical formula of agents. Thus, the neurotoxic properties of n-hexane and methyl-n-butylketone are attributable to a common gamma-diketone metabolite (2,5-HD), whereas chemically related compounds (i.e., heptane, pentane) have failed to produce experimental neuropathy. Nontoxins also can enhance toxic situations. Symptoms may intensify for months after exposure is stopped (coasting), and, conversely, dysfunction may not appear until years of low level exposure. Preexisting subclinical nervous system dysfunction (i.e., carpal tunnel syndrome) may first become manifest after toxic exposure (unmasking phenomena). The onset of symptoms, particularly negative symptoms, can be insidious and may continue undetected by patient and physician. It is suggested that neurotoxic damage in early life can enhance late life central nervous system dysfunction, such as Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)147-155
Number of pages9
JournalInternational Journal of Toxicology
Volume8
Issue number1
DOIs
StatePublished - 1989

Fingerprint

Poisons
Screening
Neurology
Metabolites
Neurotoxicity Syndromes
Heptanes
Carpal Tunnel Syndrome
Acrylamide
Hallucinations
Clinical laboratories
Nervous System
Signs and Symptoms
Parkinson Disease
Medical imaging
Seizures
Central Nervous System
Physicians
Tunnels

ASJC Scopus subject areas

  • Toxicology

Cite this

Screening for Neurotoxic Disease in Humans. / Arezzo, Joseph C.; Schaumburg, Herbert H.

In: International Journal of Toxicology, Vol. 8, No. 1, 1989, p. 147-155.

Research output: Contribution to journalArticle

Arezzo, Joseph C. ; Schaumburg, Herbert H. / Screening for Neurotoxic Disease in Humans. In: International Journal of Toxicology. 1989 ; Vol. 8, No. 1. pp. 147-155.
@article{56048865e7b64db6b12d4d4060b56818,
title = "Screening for Neurotoxic Disease in Humans",
abstract = "Detection of neurotoxic disease is a formidable task requiring clinical, epidemiologic and detective skills,(1) Rarely does neurotoxic insult occur in isolation, and rarely are precise details of the putative exposure known. False positive and false negative diagnoses of neurotoxicity are common because of the similarity of the major signs and symptoms with those associated with metabolic, traumatic, or age-related diseases. No single test or sign is pathognomonic for neurotoxic disease; routine clinical laboratory results and imaging procedures are generally of Little value. Exposure to a specific toxin can result in a vastly different clinical profile depending on the magnitude and route of exposure. For example, acute high level exposure to acrylamide causes a toxic encephalopathy with convulsions and hallucinations; prolonged low level exposure causes distal sensory loss. Since metabolites are often the toxic moiety, it is rarely possible to predict neurotoxicity by examining the chemical formula of agents. Thus, the neurotoxic properties of n-hexane and methyl-n-butylketone are attributable to a common gamma-diketone metabolite (2,5-HD), whereas chemically related compounds (i.e., heptane, pentane) have failed to produce experimental neuropathy. Nontoxins also can enhance toxic situations. Symptoms may intensify for months after exposure is stopped (coasting), and, conversely, dysfunction may not appear until years of low level exposure. Preexisting subclinical nervous system dysfunction (i.e., carpal tunnel syndrome) may first become manifest after toxic exposure (unmasking phenomena). The onset of symptoms, particularly negative symptoms, can be insidious and may continue undetected by patient and physician. It is suggested that neurotoxic damage in early life can enhance late life central nervous system dysfunction, such as Parkinson's disease.",
author = "Arezzo, {Joseph C.} and Schaumburg, {Herbert H.}",
year = "1989",
doi = "10.3109/10915818909009101",
language = "English (US)",
volume = "8",
pages = "147--155",
journal = "International Journal of Toxicology",
issn = "1091-5818",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Screening for Neurotoxic Disease in Humans

AU - Arezzo, Joseph C.

AU - Schaumburg, Herbert H.

PY - 1989

Y1 - 1989

N2 - Detection of neurotoxic disease is a formidable task requiring clinical, epidemiologic and detective skills,(1) Rarely does neurotoxic insult occur in isolation, and rarely are precise details of the putative exposure known. False positive and false negative diagnoses of neurotoxicity are common because of the similarity of the major signs and symptoms with those associated with metabolic, traumatic, or age-related diseases. No single test or sign is pathognomonic for neurotoxic disease; routine clinical laboratory results and imaging procedures are generally of Little value. Exposure to a specific toxin can result in a vastly different clinical profile depending on the magnitude and route of exposure. For example, acute high level exposure to acrylamide causes a toxic encephalopathy with convulsions and hallucinations; prolonged low level exposure causes distal sensory loss. Since metabolites are often the toxic moiety, it is rarely possible to predict neurotoxicity by examining the chemical formula of agents. Thus, the neurotoxic properties of n-hexane and methyl-n-butylketone are attributable to a common gamma-diketone metabolite (2,5-HD), whereas chemically related compounds (i.e., heptane, pentane) have failed to produce experimental neuropathy. Nontoxins also can enhance toxic situations. Symptoms may intensify for months after exposure is stopped (coasting), and, conversely, dysfunction may not appear until years of low level exposure. Preexisting subclinical nervous system dysfunction (i.e., carpal tunnel syndrome) may first become manifest after toxic exposure (unmasking phenomena). The onset of symptoms, particularly negative symptoms, can be insidious and may continue undetected by patient and physician. It is suggested that neurotoxic damage in early life can enhance late life central nervous system dysfunction, such as Parkinson's disease.

AB - Detection of neurotoxic disease is a formidable task requiring clinical, epidemiologic and detective skills,(1) Rarely does neurotoxic insult occur in isolation, and rarely are precise details of the putative exposure known. False positive and false negative diagnoses of neurotoxicity are common because of the similarity of the major signs and symptoms with those associated with metabolic, traumatic, or age-related diseases. No single test or sign is pathognomonic for neurotoxic disease; routine clinical laboratory results and imaging procedures are generally of Little value. Exposure to a specific toxin can result in a vastly different clinical profile depending on the magnitude and route of exposure. For example, acute high level exposure to acrylamide causes a toxic encephalopathy with convulsions and hallucinations; prolonged low level exposure causes distal sensory loss. Since metabolites are often the toxic moiety, it is rarely possible to predict neurotoxicity by examining the chemical formula of agents. Thus, the neurotoxic properties of n-hexane and methyl-n-butylketone are attributable to a common gamma-diketone metabolite (2,5-HD), whereas chemically related compounds (i.e., heptane, pentane) have failed to produce experimental neuropathy. Nontoxins also can enhance toxic situations. Symptoms may intensify for months after exposure is stopped (coasting), and, conversely, dysfunction may not appear until years of low level exposure. Preexisting subclinical nervous system dysfunction (i.e., carpal tunnel syndrome) may first become manifest after toxic exposure (unmasking phenomena). The onset of symptoms, particularly negative symptoms, can be insidious and may continue undetected by patient and physician. It is suggested that neurotoxic damage in early life can enhance late life central nervous system dysfunction, such as Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=84973759305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973759305&partnerID=8YFLogxK

U2 - 10.3109/10915818909009101

DO - 10.3109/10915818909009101

M3 - Article

AN - SCOPUS:84973759305

VL - 8

SP - 147

EP - 155

JO - International Journal of Toxicology

JF - International Journal of Toxicology

SN - 1091-5818

IS - 1

ER -